The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Elias Jabbour, Guillermo Garcia-Manero, A. Megan Cornelison, Jorge E. Cortes, Farhad Ravandi, Naval Daver, Tapan Kadia, Angela Teng, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.

Original languageEnglish (US)
Pages (from-to)390-394
Number of pages5
JournalLeukemia and Lymphoma
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

decitabine
Myelodysplastic Syndromes
Survival
Blood Platelets
Acute Myeloid Leukemia
Disease Progression
Erythrocytes
Regression Analysis
Clinical Trials

Keywords

  • Dacogen
  • Decitabine
  • Myelodysplastic syndromes
  • Retrospective study

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. / Jabbour, Elias; Garcia-Manero, Guillermo; Cornelison, A. Megan; Cortes, Jorge E.; Ravandi, Farhad; Daver, Naval; Kadia, Tapan; Teng, Angela; Kantarjian, Hagop.

In: Leukemia and Lymphoma, Vol. 56, No. 2, 01.02.2015, p. 390-394.

Research output: Contribution to journalArticle

Jabbour, E, Garcia-Manero, G, Cornelison, AM, Cortes, JE, Ravandi, F, Daver, N, Kadia, T, Teng, A & Kantarjian, H 2015, 'The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes', Leukemia and Lymphoma, vol. 56, no. 2, pp. 390-394. https://doi.org/10.3109/10428194.2014.914192
Jabbour, Elias ; Garcia-Manero, Guillermo ; Cornelison, A. Megan ; Cortes, Jorge E. ; Ravandi, Farhad ; Daver, Naval ; Kadia, Tapan ; Teng, Angela ; Kantarjian, Hagop. / The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 2. pp. 390-394.
@article{de40079e656341159fab92a6c624c771,
title = "The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes",
abstract = "Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22{\%} vs. 10{\%}; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.",
keywords = "Dacogen, Decitabine, Myelodysplastic syndromes, Retrospective study",
author = "Elias Jabbour and Guillermo Garcia-Manero and Cornelison, {A. Megan} and Cortes, {Jorge E.} and Farhad Ravandi and Naval Daver and Tapan Kadia and Angela Teng and Hagop Kantarjian",
year = "2015",
month = "2",
day = "1",
doi = "10.3109/10428194.2014.914192",
language = "English (US)",
volume = "56",
pages = "390--394",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Cornelison, A. Megan

AU - Cortes, Jorge E.

AU - Ravandi, Farhad

AU - Daver, Naval

AU - Kadia, Tapan

AU - Teng, Angela

AU - Kantarjian, Hagop

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.

AB - Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.

KW - Dacogen

KW - Decitabine

KW - Myelodysplastic syndromes

KW - Retrospective study

UR - http://www.scopus.com/inward/record.url?scp=84923930253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923930253&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.914192

DO - 10.3109/10428194.2014.914192

M3 - Article

C2 - 24844364

AN - SCOPUS:84923930253

VL - 56

SP - 390

EP - 394

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -